With over $117 million carryover funds for Cancer Moonshot activities in fiscal year (FY) 2024, funding was allocated into four budget mechanisms: research grants, R&D contracts, intramural research, and research management and support, as shown in the chart below.
Type of Mechanism | Mechanism | Number | Amount1 |
---|---|---|---|
Research Project Grants (RPGs)
| Competing | 21 | $16,985,816 |
Noncompeting | 32 | $21,070,638 | |
Admin Supplements | 0 | $2,653,674 | |
Subtotal, without SBIR | 0 | $0 | |
SBIR/STTR Grants | 0 | $0 | |
Subtotal, RPGs | 53 | $40,710,128 | |
Centers
| Cancer Centers-P30s | 0 | $721,495 |
P50s | 2 | $862,041 | |
Cooperative Agreements-U54s/U41s | 1 | $267,596 | |
Subtotal, Centers | 3 | $1,851,132 | |
Other Research
| Resource Grants-U24s/U2Cs | $25,665,318 | |
Subtotal, Other Research | $25,665,318 | ||
Subtotal, Research Grants | $68,226,578 | ||
Intramural Research | IR Program | 0 | $4,960,447 |
Research Management & Support | RMS | 0 | $141,095 |
R&D Contracts
| R&D Contracts | $44,532,683 | |
SBIR/STTR Contracts | $0 | ||
Subtotal, R&D Contracts | $44,532,683 | ||
Total | $117,860,803 | ||
1 Includes obligations and recoveries from fiscal years 2017, 2018, 2019, 2020, 2021, 2022, and 2023 carryover accounts. |